Form 4: Kintara Therapeutics Director Acquires Options Following Merger with TuHURA Biosciences
SEC Form 4
James S. Manuso, a director of Kintara Therapeutics (now TuHURA Biosciences), acquired options to purchase common stock following the completion of a merger with TuHURA Biosciences on October 18, 2024.
Summary
- James S. Manuso, a director of Kintara Therapeutics, filed a Form 4 to report changes in beneficial ownership.
- The report indicates that on October 18, 2024, Manuso acquired options to buy 13,553 shares of common stock at an exercise price of $3.69, expiring on January 16, 2033.
- He also acquired options to buy 13,553 shares of common stock at an exercise price of $4.14, expiring on February 28, 2034.
- These acquisitions are related to the merger between Kintara Therapeutics and TuHURA Biosciences, which closed on October 18, 2024.
- As a result of the merger, Kintara Therapeutics changed its name to TuHURA Biosciences, Inc.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The document primarily reports a transaction related to a merger. The acquisition of options by a director could be seen as a slightly positive signal, but it's not definitively bullish.
Positives
- The acquisition of options by a director could be interpreted as a sign of confidence in the company's future prospects following the merger.
Future Outlook
The document does not contain specific forward-looking statements beyond the completion of the merger and the name change.
Industry Context
The merger between Kintara Therapeutics and TuHURA Biosciences is likely aimed at combining resources and expertise to advance their respective pipelines and potentially create synergies in research and development.
Stakeholder Impact
- Shareholders of both Kintara Therapeutics and TuHURA Biosciences are impacted by the merger, as their holdings are now part of the combined entity.
- Employees of both companies may experience changes as a result of the integration.
Key Dates
| Date | Description |
|---|---|
| April 2, 2024 | Date of the Agreement and Plan of Merger between Kintara Therapeutics and TuHURA Biosciences. |
| October 18, 2024 | Date of the merger between Kintara Therapeutics and TuHURA Biosciences, and the date of the options acquisition by James Manuso. |
| October 22, 2024 | Date of the Form 4 filing. |
| January 16, 2033 | Expiration date of options to buy 13,553 shares at $3.69. |
| February 28, 2034 | Expiration date of options to buy 13,553 shares at $4.14. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.